JP2018502077A - ブルトンチロシンキナーゼ阻害剤の合成 - Google Patents

ブルトンチロシンキナーゼ阻害剤の合成 Download PDF

Info

Publication number
JP2018502077A
JP2018502077A JP2017532649A JP2017532649A JP2018502077A JP 2018502077 A JP2018502077 A JP 2018502077A JP 2017532649 A JP2017532649 A JP 2017532649A JP 2017532649 A JP2017532649 A JP 2017532649A JP 2018502077 A JP2018502077 A JP 2018502077A
Authority
JP
Japan
Prior art keywords
compound
formula
ibrutinib
amino
phenoxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017532649A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502077A5 (enExample
Inventor
ベンハイム，シリル
チェン，ウェイ
ゴールドマン，エリック
ホルヴァート，アンドラス
パイ，フィリップ
スミス，マーク，エス．
ヴァーナー，エリック，ジェイ．
Original Assignee
ファーマサイクリックス エルエルシー
ファーマサイクリックス エルエルシー
ジャンセン ファーマシューティカ エヌブイ
ジャンセン ファーマシューティカ エヌブイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーマサイクリックス エルエルシー, ファーマサイクリックス エルエルシー, ジャンセン ファーマシューティカ エヌブイ, ジャンセン ファーマシューティカ エヌブイ filed Critical ファーマサイクリックス エルエルシー
Publication of JP2018502077A publication Critical patent/JP2018502077A/ja
Publication of JP2018502077A5 publication Critical patent/JP2018502077A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2017532649A 2015-01-14 2016-01-14 ブルトンチロシンキナーゼ阻害剤の合成 Pending JP2018502077A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562103507P 2015-01-14 2015-01-14
US62/103,507 2015-01-14
PCT/US2016/013424 WO2016115356A1 (en) 2015-01-14 2016-01-14 Synthesis of a bruton's tyrosine kinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020171454A Division JP2021035947A (ja) 2015-01-14 2020-10-09 ブルトンチロシンキナーゼ阻害剤の合成

Publications (2)

Publication Number Publication Date
JP2018502077A true JP2018502077A (ja) 2018-01-25
JP2018502077A5 JP2018502077A5 (enExample) 2019-02-28

Family

ID=56406389

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017532649A Pending JP2018502077A (ja) 2015-01-14 2016-01-14 ブルトンチロシンキナーゼ阻害剤の合成
JP2020171454A Pending JP2021035947A (ja) 2015-01-14 2020-10-09 ブルトンチロシンキナーゼ阻害剤の合成

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020171454A Pending JP2021035947A (ja) 2015-01-14 2020-10-09 ブルトンチロシンキナーゼ阻害剤の合成

Country Status (16)

Country Link
US (6) US20180009814A1 (enExample)
EP (1) EP3245208A4 (enExample)
JP (2) JP2018502077A (enExample)
KR (1) KR20170102887A (enExample)
CN (2) CN107108640A (enExample)
AU (2) AU2016206693A1 (enExample)
BR (1) BR112017015206B1 (enExample)
CA (2) CA2971460C (enExample)
HK (1) HK1246293A1 (enExample)
IL (4) IL322449A (enExample)
MA (1) MA41350A (enExample)
MX (2) MX366827B (enExample)
RU (1) RU2017128308A (enExample)
SG (2) SG11201705678YA (enExample)
WO (1) WO2016115356A1 (enExample)
ZA (1) ZA201704338B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020066629A (ja) * 2018-10-22 2020-04-30 ファイザー・インク ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
JP2022533219A (ja) * 2019-05-21 2022-07-21 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｔｋ阻害剤を調製するためのプロセス及び中間体
JP2022533747A (ja) * 2019-05-21 2022-07-25 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｔｋ阻害剤を調製するためのプロセス及び中間体

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016127915A1 (zh) * 2015-02-12 2016-08-18 上海度德医药科技有限公司 伊布替尼的制备方法
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR102793563B1 (ko) 2016-03-04 2025-04-11 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
CN109206426B (zh) * 2017-07-06 2021-10-08 上海复星星泰医药科技有限公司 吡唑并嘧啶类化合物的制备方法
JP7166331B2 (ja) 2017-08-01 2022-11-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 中間体化合物及び方法
CN107814804A (zh) * 2017-10-27 2018-03-20 广州科锐特生物科技有限公司 依鲁替尼的制备方法
EP4353222A1 (en) 2018-03-19 2024-04-17 Taiho Pharmaceutical Co., Ltd. Use of sodium alkyl sulfate
EP3787751A1 (en) 2018-05-03 2021-03-10 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
KR102742083B1 (ko) 2018-11-09 2024-12-16 다이호야쿠힌고교 가부시키가이샤 디메톡시벤젠 화합물의 제조 방법
CN109988175A (zh) * 2019-04-28 2019-07-09 梯尔希（南京）药物研发有限公司 一种依鲁替尼-d5的制备方法
EP4281454B1 (en) 2021-01-21 2025-03-05 Synthon B.V. Process for making ibrutinib
CN114853662B (zh) * 2021-02-05 2024-01-12 四川青木制药有限公司 手性肼基哌啶衍生物的制备方法
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010235628A (ja) * 2006-09-22 2010-10-21 Pharmacyclics Inc ブルートンチロシンキナーゼ阻害剤
JP2013507448A (ja) * 2009-10-12 2013-03-04 ファーマサイクリクス，インコーポレイテッド ブルトン型チロシンキナーゼの阻害剤
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
WO2014022390A1 (en) * 2012-07-30 2014-02-06 Concert Pharmaceuticals, Inc. Deuterated ibrutinib
CN103626774A (zh) * 2013-11-20 2014-03-12 苏州明锐医药科技有限公司 伊鲁替尼的制备方法
US20140275126A1 (en) * 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550214A (en) * 1981-01-05 1985-10-29 Polaroid Corporation Blocked vinyl biphenyl compounds
US4874822A (en) * 1988-04-07 1989-10-17 Minnesota Mining And Manufacturing Company Process for the acrylamidoacylation of alcohols
MXPA06007326A (es) * 2003-12-23 2007-01-26 Astex Therapeutics Ltd Derivados de pirazol como moduladores de proteina cinasa.
NZ579911A (en) * 2007-03-28 2012-05-25 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN105471823B (zh) * 2014-09-03 2018-10-26 阿里巴巴集团控股有限公司 一种敏感信息处理方法、装置、服务器及安全判定系统
EP3248979B1 (en) * 2015-01-21 2021-04-14 Hefei Institutes of Physical Science, Chinese Academy of Sciences Novel inhibitor of flt3 kinase and use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010235628A (ja) * 2006-09-22 2010-10-21 Pharmacyclics Inc ブルートンチロシンキナーゼ阻害剤
JP2013507448A (ja) * 2009-10-12 2013-03-04 ファーマサイクリクス，インコーポレイテッド ブルトン型チロシンキナーゼの阻害剤
WO2014022390A1 (en) * 2012-07-30 2014-02-06 Concert Pharmaceuticals, Inc. Deuterated ibrutinib
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
US20140275126A1 (en) * 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
CN103626774A (zh) * 2013-11-20 2014-03-12 苏州明锐医药科技有限公司 伊鲁替尼的制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
THE IP.COM JOURNAL, vol. 14(9A), JPN6019040255, 2014, pages 1 - 2, ISSN: 0004281120 *
THE IP.COM JOURNAL, vol. 15(1B), JPN6019040256, 2015, pages 1 - 2, ISSN: 0004281121 *
第５版実験化学講座１３ 有機化合物の合成Ｉ−炭化水素・ハロゲン化物−, JPN6020019412, 20 February 2004 (2004-02-20), ISSN: 0004281122 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020066629A (ja) * 2018-10-22 2020-04-30 ファイザー・インク ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
US12116368B2 (en) 2018-10-22 2024-10-15 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto
JP2022533219A (ja) * 2019-05-21 2022-07-21 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｔｋ阻害剤を調製するためのプロセス及び中間体
JP2022533747A (ja) * 2019-05-21 2022-07-25 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｔｋ阻害剤を調製するためのプロセス及び中間体
US12215110B2 (en) 2019-05-21 2025-02-04 Janssen Pharmaceutica Nv Processes and intermediates for preparing a Btk inhibitor
JP7658916B2 (ja) 2019-05-21 2025-04-08 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｔｋ阻害剤を調製するためのプロセス及び中間体
US12459948B2 (en) 2019-05-21 2025-11-04 Janssen Pharmaceutica Nv Processes and intermediates for preparing a Btk inhibitor
JP7774448B2 (ja) 2019-05-21 2025-11-21 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｔｋ阻害剤を調製するためのプロセス及び中間体

Also Published As

Publication number Publication date
MA41350A (fr) 2017-11-21
SG11201705678YA (en) 2017-08-30
CN107108640A (zh) 2017-08-29
US20220098200A1 (en) 2022-03-31
AU2016206693A1 (en) 2017-07-13
IL322449A (en) 2025-09-01
WO2016115356A1 (en) 2016-07-21
JP2021035947A (ja) 2021-03-04
US20250197404A1 (en) 2025-06-19
US20240158400A1 (en) 2024-05-16
IL253020A0 (en) 2017-08-31
MX394327B (es) 2025-03-24
EP3245208A1 (en) 2017-11-22
US20200347064A1 (en) 2020-11-05
HK1246293A1 (zh) 2018-09-07
IL274716A (en) 2020-07-30
MX2017009154A (es) 2017-10-12
RU2017128308A3 (enExample) 2019-10-24
CA2971460A1 (en) 2016-07-21
SG10201906517VA (en) 2019-08-27
KR20170102887A (ko) 2017-09-12
US20180009814A1 (en) 2018-01-11
MX2019008815A (es) 2019-09-26
US20190367518A1 (en) 2019-12-05
CA2971460C (en) 2023-10-10
RU2017128308A (ru) 2019-02-14
AU2020230323A1 (en) 2020-10-01
CN113816962A (zh) 2021-12-21
IL308276A (en) 2024-01-01
BR112017015206B1 (pt) 2023-04-11
ZA201704338B (en) 2023-10-25
MX366827B (es) 2019-07-25
CA3210320A1 (en) 2016-07-21
BR112017015206A2 (pt) 2018-06-19
EP3245208A4 (en) 2018-10-17

Similar Documents

Publication Publication Date Title
JP2018502077A (ja) ブルトンチロシンキナーゼ阻害剤の合成
TWI658042B (zh) 雜環化合物的合成
TWI496781B (zh) 製備｛４，６－二胺基－２－［１－（２－氟苯甲基）－１Ｈ－吡唑并［３，４－ｂ］吡啶－３－基］嘧啶－５－基｝甲基胺基甲酸甲酯之方法及其使用作為醫藥活性化合物之純化
CA2903797C (en) Processes for the preparation of an apoptosis-inducing agent
EP2794575B1 (en) Synthesis of triazolopyrimidine compounds
EP3215493B1 (en) Synthesis of copanlisib and its dihydrochloride salt
JP6268093B2 (ja) 縮合複素環誘導体の製造方法およびその製造中間体
KR102477924B1 (ko) 인돌 카르복스아미드 화합물을 제조하는 방법
US8563718B2 (en) Thiazolyl-pyrazolopyrimidine compounds as synthetic intermediates and related synthetic processes
KR20200092945A (ko) 레날리도마이드의 결정형
TWI389912B (zh) 用於製備ｎ－〔５－（３－二甲胺基－丙烯醯基）－２－氟苯基〕－ｎ－甲基－乙醯胺之方法
JP2023179354A (ja) Ｈ－ホスホネート法を用いたモルフォリノ核酸の製造方法
CN110759923B (zh) 嘧啶并吡咯并哒嗪衍生物、其中间体、制备方法、药物组合物和用途
BR122022026564B1 (pt) Processos para a preparação de 1-((r)-3-(4-amino-3-(4-fenoxifenil)-1hpirazol[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona (ibrutinibe) e compostos
JP5034277B2 (ja) ３−（ｎ−アシルアミノ）−３−（４−テトラヒドロピラニル）−２−オキソプロパン酸エステル及び３−（ｎ−アシルアミノ）−３−（４−テトラヒドロピラニル）−２−オキソプロパノヒドラジドの製造方法
WO2022202814A1 (ja) ピリミジン化合物の製造方法
TW202134242A (zh) 用於生產式(i)之方法及中間體
WO2022032644A1 (zh) 一种取代的咪唑并[1,2-a]吡啶-2-基酰胺化合物的制备方法及其中间体
KR20050062944A (ko) 디이소프로필((1-((2-아미노-6-클로로-9ｈ-퓨린-9-일)메틸)사이클로프로필)옥시)-메틸포스포네이트의 새로운 제조방법
US20060217554A1 (en) Processes for producing pyrazoloacridone derivative and synthetic intermediate thereof
WO2009117278A2 (en) Processes for preparing (amino-pyrazolopyridinyl)methoxy substituted biaryl ethers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190111

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200415

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200611